文献速递糖尿病肥胖与代谢综合征

坚持极低能量饮食的青少年2型糖尿病逆转:一项先导研究

Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study.
PubMed 文献 · Diabetologia · 2016-11-26

这项先导研究纳入8例7-16岁2型糖尿病合并肥胖青少年,接受8周极低能量饮食(<3360 kJ/天)后转为低热量饮食至34周。8周时HbA1c、2hG和肝脂肪含量均显著下降,3例胰岛素治疗者全部停药;34周时5例坚持者中4例不再符合美国糖尿病协会2型糖尿病标准。作者认为极低低能量饮食对部分青少年2型糖尿病是可行治疗选择,但需更大样本对照试验验证。

要点

  • 8周极低能量饮食后HbA1c从8.1%降至6.6%,2hG从15.6 mmol/l降至11.3 mmol/l
  • 8周时肝脂肪从14.7%降至5.8%,仅3/8例符合NAFLD标准(基线8/8例)
  • 34周时5例坚持者中4例不再符合美国糖尿病协会2型糖尿病标准

核心结论

  • 极低能量饮食似乎是部分接受二甲双胍治疗的青少年2型糖尿病患者的可行治疗选择。
  • 参与并坚持极低能量饮食的青少年可实现快速体重下降、肝脂肪大幅减少和2型糖尿病逆转。
  • 作者认为极低能量饮食有潜力作为新诊断青少年的第一线治疗选择。
  • 需要更大样本、设对照组和更长随访的试验来推动标准治疗改变。

研究设计与样本

  • 先导研究,纳入8例7-16岁2型糖尿病合并肥胖青少年,非药物治疗1例、二甲双胍治疗7例(其中3例同时使用胰岛素)。
  • 受试者接受8周极低能量饮食(<3360 kJ/天),随后转为低热量饮食(约6300 kJ/天)至34周。
  • 通过空腹血和口服葡萄糖耐量试验测定HbA1c、空腹血糖和餐后2小时血浆葡萄糖(2hG),用质子磁共振波谱定量肝脂肪浓度。
  • 坚持定义为8周极低能量饮食期间体重下降≥5%。

主要发现

  • 8周时坚持者(n=5)和非坚持者(n=3)体重下降中位数分别为7.5%和0.5%。
  • 总体8周时HbA1c较基线显著降低(均值[SE] 8.1%[0.7%]降至6.6%[0.5%],p=0.004)。
  • 总体8周时2hG较基线显著降低(15.6[1.6] mmol/l降至11.3[1.0] mmol/l,p=0.009)。
  • 肝脂肪从基线14.7%[2.2%]显著降至8周时5.8%[1.7%](p=0.001);8周时仅3/8例符合非酒精性脂肪性肝病(NAFLD)标准(≥5.5%),基线为8/8例。
  • 基线时3例胰岛素治疗者在8周极低能量饮食期间全部停用胰岛素;34周时坚持者(n=5)体重下降12.3%,无人符合NAFLD标准,4例不符合美国糖尿病协会2型糖尿病标准。

临床怎么用

  • 作者认为极低能量饮食有潜力作为新诊断青少年2型糖尿病的第一线治疗选择。
  • 作者指出需要更大样本、设对照组和更长随访的试验来推动标准治疗改变。

局限性

  • 原文指出需要更大样本、设对照组和更长随访的试验来推动标准治疗改变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of the study was to investigate whether a very-low-energy diet (VLED) is a feasible and acceptable treatment option for type 2 diabetes in children and adolescents, and whether adherence can lead to rapid weight loss, reversal of type 2 diabetes and reduced liver fat as seen in adult studies. METHODS: Eight participants with type 2 diabetes and obesity, aged 7-16 years, non-medicated (n = 1) or treated with metformin (n = 7) and in some cases insulin (n = 3), followed a VLED (<3360 kJ/day) for 8 weeks, then transitioned to a hypocaloric diet (∼6300 kJ/day) that they followed to 34 weeks. HbA1c, fasting glucose and 2 h post-glucose load plasma glucose (2hG) were determined from fasting blood and an OGTT. Liver fat concentration was quantified using proton magnetic resonance spectroscopy. Adherence was defined as ≥5% weight loss during the 8 week VLED. RESULTS: Adherers (n = 5) and non-adherers (n = 3) had median weight loss of 7.5% and 0.5%, respectively, at 8 weeks. Overall, HbA1c (mean [SE] 8.1% [0.7%] to 6.6% [0.5%]; p = 0.004) and 2hG (15.6 [1.6] mmol/l to 11.3 [1.0] mmol/l; p = 0.009) were significantly reduced at 8 weeks compared with baseline. Liver fat was also significantly reduced from baseline (14.7% [2.2%]) to 8 weeks (5.8% [1.7%]; p = 0.001). Only three out of eight participants met non-alcoholic fatty liver disease (NAFLD) criteria (≥5.5%) at 8 weeks, compared with eight out of eight at baseline. The three participants on insulin therapy at baseline were able to cease therapy during the 8 week VLED. At 34 weeks, adherers (n = 5) achieved 12.3% weight loss, none met NAFLD criteria and four did not meet American Diabetes Association criteria for type 2 diabetes. CONCLUSIONS/INTERPRETATION: A VLED appears to be a feasible treatment option for some youth with type 2 diabetes on metformin therapy. Youth who agree to participate and adhere to a VLED achieve rapid weight loss, dramatic reductions in liver fat and reversal of type 2 diabetes. This highlights the capacity of a VLED to be used as a first-line treatment option in newly diagnosed youth. A larger trial with a control group and longer follow-up will be required to encourage a change in standard treatment. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registration Number (ACTRN) ACTRN12616000375459 ( www.ANZCTR.org.au/ACTRN12616000375459.aspx ).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gow ML, Baur LA, Johnson NA, et al. Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study. Diabetologia. 2016. PMID: 27889809. doi:10.1007/s00125-016-4163-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。